Epigenomics establishes American Depositary Receipt program

11-Jul-2013 - USA

Epigenomics AG (ECX) announced that the Company has established a Level 1 ADR program in the U.S.A. BNY Mellon has been appointed as the depositary bank for the ADR program. ADRs of Epigenomics are US dollar negotiable certificates representing ordinary shares of the Company at a ratio of five ordinary shares to one Epigenomics ADR. Epigenomics ADRs can be traded on the US OTC market effective as of July 9, 2013 under the ticker symbol EPGNY. Ordinary Epigenomics shares are traded in Frankfurt Prime Standard, Germany, under the ticker symbol ECX.

“In the light of our focused US strategy and the upcoming decision about the approval of our blood-based test for the early detection of colorectal cancer, Epi proColon®, we experience growing interest of US investors,” explained Dr. Thomas Taapken, CEO/CFO of Epigenomics AG. “We established the ADR program as a service to offer those investors an easy way to buy our shares and to consequently broaden the shareholder base in our core market.”

Other news from the department business & finance

Most read news

More news from our other portals

Fighting cancer: latest developments and advances